Star Imaging and Path Lab Ltd

As of November 19, 2025, Star Imaging is considered very expensive and overvalued with a PE ratio of 14.83, an EV to EBITDA of 9.24, and a ROE of 33.81%, especially given its recent underperformance of -4.31% compared to the Sensex's 0.85%.

Star Imaging has shown significant growth in shareholder's funds and total assets over the past four years, with shareholder's funds increasing to 47.15 Cr and total assets to 98.16 Cr by March 2025. Profit before tax improved to 21.00 Cr, although cash flow from operating activities turned negative, indicating potential cash generation challenges.